Teleflex Secures FDA Approval for First Licensed Freeze-Dried Plasma Product
Event summary
- Teleflex received FDA BLA approval for EZPLAZ™ Freeze Dried Plasma (FDP) on July 29, 2026.
- EZPLAZ™ FDP is the first FDA-licensed freeze-dried plasma product, addressing logistical challenges in prehospital and battlefield settings.
- The product uses patented flexible plastic bag technology, offering a 12-month shelf life and reconstitution in 1-2.5 minutes.
- Development was supported by a Cooperative Research and Development Agreement (CRADA) with the Defense Health Agency.
The big picture
Teleflex’s FDA approval for EZPLAZ™ FDP addresses a critical gap in emergency and battlefield medicine, where logistical constraints limit the use of traditional plasma products. The product’s shelf-stable and easy-to-transport design aligns with broader industry trends toward enhancing medical capabilities in remote and austere environments. This milestone positions Teleflex as a key player in the evolving landscape of trauma care and military healthcare.
What we're watching
- Market Adoption
- How quickly EZPLAZ™ FDP will be integrated into prehospital and battlefield medical protocols.
- Competitive Response
- Whether existing plasma product manufacturers will accelerate development of similar freeze-dried alternatives.
- Revenue Impact
- The pace at which Teleflex can commercialize the product and its contribution to the company's emergency medicine portfolio.
Related topics